Tenet Healthcare (THC) News Today

Tenet Healthcare Corporation (NYSE:THC) – Below is a summary of recent news items that may be influencing THC’s share performance, ordered by potential positive, neutral and negative impacts.

• Positive Sentiment: Bank of America raised its price target on THC from $205.00 to $225.00 and reiterated a “Buy” rating, reflecting increased analyst confidence in the company’s outlook. Bank of America Price Target Lift
• Positive Sentiment: Shares of THC reached a new 12-month high following an analyst upgrade, underscoring strong market momentum. 12-Month High Alert
• Positive Sentiment: Short interest in THC shares declined by 22.7% in August, suggesting reduced bearish pressure on the stock. Short Interest Decline
• Positive Sentiment: A lawsuit over 401(k) forfeiture claims against Tenet was dropped, removing a potential legal overhang. 401(k) Suit Dropped
• Neutral Sentiment: Zacks published an analysis discussing whether THC qualifies as a top momentum stock, weighing its recent performance and market trends. Momentum Stock Analysis
• Neutral Sentiment: Another Zacks piece explores whether investors are undervaluing THC, focusing on earnings revisions and valuation metrics. Undervaluation Analysis
• Neutral Sentiment: Zacks also noted THC as a “fast-paced mover at a bargain,” highlighting recent momentum alongside reasonable valuations for value investors. Value Investor Screen
• Negative Sentiment: CEO Saumya Sutaria sold 78,762 shares of THC at an average price of $190.78, reducing her stake by 17.6%, which could signal insider profit-taking or diversification concerns. Insider Sale Filing